Zhejiang Huahai Pharmaceutical Co., Ltd. (SHA:600521)

Market Cap	21.47B +0.8%
Revenue (ttm)	8.55B -9.2%
Net Income	373.17M -67.4%
EPS	0.25 -68.5%
Shares Out	1.49B
PE Ratio	80.06
Forward PE	19.47
Dividend	0.10 (0.68%)
Ex-Dividend Date	Jul 10, 2025

Volume	20,151,141
Open	14.68
Previous Close	14.74
Day's Range	14.25 - 14.74
52-Week Range	14.26 - 27.97
Beta	0.16
Analysts	Hold
Price Target	17.70 (+22.83%)
Earnings Date	Aug 28, 2026

About SHA:600521

Zhejiang Huahai Pharmaceutical Co., Ltd. engaged in the research, development, production and sales of generic drugs, biological drugs, and APIs in multiple dosage forms in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as polyethylene bottles and polypropylene caps for pharmaceuticals. In addition, the company offers contract manufacturing and other services, as well as import and export trade serv...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 8,797
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600521

Financial Performance

In 2025, SHA:600521's revenue was 8.59 billion, a decrease of -10.06% compared to the previous year's 9.55 billion. Earnings were 266.40 million, a decrease of -76.19%.

Analyst Summary

According to 3 analysts, the average rating for 600521 stock is "Hold." The 12-month stock price target is ¥17.70, which is an increase of 22.83% from the latest price.

Price Target

¥17.70

(22.83% upside)

Analyst Consensus: Hold